NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT03008278 2026-02-03
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04209686 2025-12-03
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05379972 2025-07-16
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
Phase 2 Active not recruiting
NCT01924533 2024-03-22
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
AstraZeneca
Phase 3 Completed
NCT01063517 2023-07-20
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
AstraZeneca
Phase 2 Completed
NCT05411679 2023-06-12
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Ellipses Pharma
Phase 2 Withdrawn
NCT03829345 2019-07-08
SOLAR
Royal Marsden NHS Foundation Trust
Phase 2 Unknown